Hyperlipidemia - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 212 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hyperlipidemia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Hyperlipidemia - Pipeline Review, H1 2016', provides an overview of the Hyperlipidemia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Hyperlipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperlipidemia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperlipidemia
- The report reviews pipeline therapeutics for Hyperlipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Hyperlipidemia therapeutics and enlists all their major and minor projects
- The report assesses Hyperlipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Hyperlipidemia

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Hyperlipidemia Overview 9
Therapeutics Development 10
Pipeline Products for Hyperlipidemia - Overview 10
Pipeline Products for Hyperlipidemia - Comparative Analysis 11
Hyperlipidemia - Therapeutics under Development by Companies 12
Hyperlipidemia - Therapeutics under Investigation by Universities/Institutes 16
Hyperlipidemia - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Hyperlipidemia - Products under Development by Companies 21
Hyperlipidemia - Products under Investigation by Universities/Institutes 25
Hyperlipidemia - Companies Involved in Therapeutics Development 26
Acasti Pharma Inc. 26
Allergan Plc 27
Alnylam Pharmaceuticals, Inc. 28
Amgen Inc. 29
Arbutus Biopharma Corporation 30
Arisaph Pharmaceuticals, Inc. 31
Astellas Pharma Inc. 32
AstraZeneca Plc 33
BASF SE 34
BCWorld Pharm Co. Ltd. 35
Cadila Pharmaceuticals Ltd. 36
Cardax Pharmaceuticals, Inc. 37
Catabasis Pharmaceuticals, Inc. 38
CJ HealthCare Corp. 39
CymaBay Therapeutics, Inc. 40
Daewoong Pharmaceutical Co., Ltd. 41
Daiichi Sankyo Company, Limited 42
Esperion Therapeutics, Inc. 43
HanAll Biopharma Co., Ltd. 44
Hanmi Pharmaceuticals, Co. Ltd. 45
Huons Co., Ltd. 46
Hyundai Pharmaceutical Co., Ltd. 47
Innovent Biologics, Inc. 48
Jeil Pharmaceutical Co., Ltd. 49
Kowa Company, Ltd. 50
LG Life Science LTD. 51
Lotus Pharmaceutical Co., Ltd. 52
Pfizer Inc. 53
Pharmena SA 54
Prometheon Pharma, LLC 55
Protalix BioTherapeutics, Inc. 56
Sancilio & Company, Inc. 57
Thetis Pharmaceuticals LLC 58
Yuhan Corporation 59
Zydus Cadila Healthcare Limited 60
Hyperlipidemia - Therapeutics Assessment 61
Assessment by Monotherapy Products 61
Assessment by Combination Products 62
Assessment by Target 63
Assessment by Mechanism of Action 66
Assessment by Route of Administration 69
Assessment by Molecule Type 71
Drug Profiles 73
(amlodipine besylate + atorvastatin calcium + valsartan) - Drug Profile 73
(amlodipine besylate + rosuvastatin calcium + valsartan) - Drug Profile 74
(atorvastatin calcium + losartan potassium) - Drug Profile 75
(atorvastatin calcium + metformin hydrochloride) XR - Drug Profile 76
(candesartan + rosuvastatin calcium) - Drug Profile 77
(gemigliptin + rosuvastatin calcium) - Drug Profile 78
(metformin hydrochloride SR + rosuvastatin calcium) - Drug Profile 79
AEM-28 - Drug Profile 80
AEM-2802 - Drug Profile 81
AEM-2814 - Drug Profile 82
ALN-AC3 - Drug Profile 83
ALN-ANG - Drug Profile 84
ARI-3037MO - Drug Profile 85
AS-1708727 - Drug Profile 86
BCWPC-001 - Drug Profile 87
bempedoic acid - Drug Profile 88
bezafibrate ER - Drug Profile 90
BH-03004 - Drug Profile 91
BioE-1115 - Drug Profile 92
bococizumab - Drug Profile 93
BSN-272 - Drug Profile 94
CAT-2000 Series - Drug Profile 95
CAT-2003 - Drug Profile 96
CDX-085 - Drug Profile 97
centatin - Drug Profile 99
DS-8312 - Drug Profile 100
DWJ-1330 - Drug Profile 101
DWJ-1351 - Drug Profile 102
etanercept biosimilar - Drug Profile 103
evolocumab - Drug Profile 104
gemcabene calcium - Drug Profile 107
HOB-071 - Drug Profile 108
HU-012 - Drug Profile 109
IBI-306 - Drug Profile 110
icosabutate - Drug Profile 111
ISIS-APOCIIILRx - Drug Profile 112
JLP-1302 - Drug Profile 113
JLP-1401 - Drug Profile 114
K-312 - Drug Profile 115
leucine + niacin - Drug Profile 116
MAT-9001 - Drug Profile 117
MBX-8025 - Drug Profile 118
NKPL-66 - Drug Profile 120
Oligonucleotide for Hyperlipidemia and Atherosclerosis - Drug Profile 122
omega-3-carboxylic acids - Drug Profile 123
PF-06427878 - Drug Profile 125
PF-06815345 - Drug Profile 126
pitavastatin CR - Drug Profile 127
Protein to Inhibit HMG-CoA Reductase for Hyperlipidemia - Drug Profile 128
saroglitazar - Drug Profile 129
SC-401 - Drug Profile 130
Small Molecule for Hyperlipidemia - Drug Profile 131
Small Molecule for Hypertriglyceridaemia - Drug Profile 132
Small Molecule for Hypertriglyceridemia - Drug Profile 133
Small Molecule for Type 2 Diabetes and Hyperlipidemia - Drug Profile 134
Small Molecule to Inhibit TRIP-Br2 for Metabolic Disorders - Drug Profile 135
Small Molecules for Dyslipidemia and Hypertriglyceridemia - Drug Profile 136
Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile 137
TKM-HTG - Drug Profile 139
TKMApoC-3 - Drug Profile 140
TP-101 - Drug Profile 141
TRIA-662 - Drug Profile 142
volanesorsen sodium - Drug Profile 144
YH-22189 - Drug Profile 146
Hyperlipidemia - Recent Pipeline Updates 147
Hyperlipidemia - Dormant Projects 190
Hyperlipidemia - Dormant Projects 190
Hyperlipidemia - Discontinued Products 198
Hyperlipidemia - Product Development Milestones 199
Featured News & Press Releases 199
Appendix 207
Methodology 207
Coverage 207
Secondary Research 207
Primary Research 207
Expert Panel Validation 207
Contact Us 207
Disclaimer 208

List of Tables
Number of Products under Development for Hyperlipidemia, H1 2016 14
Number of Products under Development for Hyperlipidemia - Comparative Analysis, H1 2016 15
Number of Products under Development by Companies, H1 2016 17
Number of Products under Development by Companies, H1 2016 (Contd..1) 18
Number of Products under Development by Companies, H1 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2016 20
Comparative Analysis by Late Stage Development, H1 2016 21
Comparative Analysis by Clinical Stage Development, H1 2016 22
Comparative Analysis by Early Stage Development, H1 2016 23
Comparative Analysis by Unknown Stage Development, H1 2016 24
Products under Development by Companies, H1 2016 25
Products under Development by Companies, H1 2016 (Contd..1) 26
Products under Development by Companies, H1 2016 (Contd..2) 27
Products under Development by Companies, H1 2016 (Contd..3) 28
Products under Investigation by Universities/Institutes, H1 2016 29
Hyperlipidemia - Pipeline by Acasti Pharma Inc., H1 2016 30
Hyperlipidemia - Pipeline by Allergan Plc, H1 2016 31
Hyperlipidemia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 32
Hyperlipidemia - Pipeline by Amgen Inc., H1 2016 33
Hyperlipidemia - Pipeline by Arbutus Biopharma Corporation, H1 2016 34
Hyperlipidemia - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016 35
Hyperlipidemia - Pipeline by Astellas Pharma Inc., H1 2016 36
Hyperlipidemia - Pipeline by AstraZeneca Plc, H1 2016 37
Hyperlipidemia - Pipeline by BASF SE, H1 2016 38
Hyperlipidemia - Pipeline by BCWorld Pharm Co. Ltd., H1 2016 39
Hyperlipidemia - Pipeline by Cadila Pharmaceuticals Ltd., H1 2016 40
Hyperlipidemia - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016 41
Hyperlipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2016 42
Hyperlipidemia - Pipeline by CJ HealthCare Corp., H1 2016 43
Hyperlipidemia - Pipeline by CymaBay Therapeutics, Inc., H1 2016 44
Hyperlipidemia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 45
Hyperlipidemia - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 46
Hyperlipidemia - Pipeline by Esperion Therapeutics, Inc., H1 2016 47
Hyperlipidemia - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 48
Hyperlipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 49
Hyperlipidemia - Pipeline by Huons Co., Ltd., H1 2016 50
Hyperlipidemia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016 51
Hyperlipidemia - Pipeline by Innovent Biologics, Inc., H1 2016 52
Hyperlipidemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016 53
Hyperlipidemia - Pipeline by Kowa Company, Ltd., H1 2016 54
Hyperlipidemia - Pipeline by LG Life Science LTD., H1 2016 55
Hyperlipidemia - Pipeline by Lotus Pharmaceutical Co., Ltd., H1 2016 56
Hyperlipidemia - Pipeline by Pfizer Inc., H1 2016 57
Hyperlipidemia - Pipeline by Pharmena SA, H1 2016 58
Hyperlipidemia - Pipeline by Prometheon Pharma, LLC, H1 2016 59
Hyperlipidemia - Pipeline by Protalix BioTherapeutics, Inc., H1 2016 60
Hyperlipidemia - Pipeline by Sancilio & Company, Inc., H1 2016 61
Hyperlipidemia - Pipeline by Thetis Pharmaceuticals LLC, H1 2016 62
Hyperlipidemia - Pipeline by Yuhan Corporation, H1 2016 63
Hyperlipidemia - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 64
Assessment by Monotherapy Products, H1 2016 65
Assessment by Combination Products, H1 2016 66
Number of Products by Stage and Target, H1 2016 68
Number of Products by Stage and Mechanism of Action, H1 2016 71
Number of Products by Stage and Route of Administration, H1 2016 74
Number of Products by Stage and Molecule Type, H1 2016 76
Hyperlipidemia Therapeutics - Recent Pipeline Updates, H1 2016 151
Hyperlipidemia - Dormant Projects, H1 2016 194
Hyperlipidemia - Dormant Projects (Contd..1), H1 2016 195
Hyperlipidemia - Dormant Projects (Contd..2), H1 2016 196
Hyperlipidemia - Dormant Projects (Contd..3), H1 2016 197
Hyperlipidemia - Dormant Projects (Contd..4), H1 2016 198
Hyperlipidemia - Dormant Projects (Contd..5), H1 2016 199
Hyperlipidemia - Dormant Projects (Contd..6), H1 2016 200
Hyperlipidemia - Dormant Projects (Contd..7), H1 2016 201
Hyperlipidemia - Discontinued Products, H1 2016 202